Cost‑effectiveness Analysis of Helicobacter pylori Eradication Therapy in First-Degree Relatives of Patients with Gastric Cancer
Authors:
Open Access
- 1 January 2021
- journal article
- research article
- Published by Taylor & Francis in Patient Preference and Adherence
- Vol. ume 15, 77-85
Abstract
Background: Helicobacter pylori (H. pylori) eradication therapy has been shown to reduce the risk of gastric cancer in patients who have a family history of gastric cancer in first-degree relatives. The aim of this study was to assess the cost-effectiveness of H. pylori eradication therapy in a select population in the People’s Republic of China. Methods: A Markov model was applied to evaluate the cost-effectiveness of H. pylori eradication therapy. The long-term costs of H. pylori eradication therapy were calculated from the Chinese perspective. Health outcomes were measured by quality-adjusted life years (QALYs). Epidemiological information and health utilities used in the model were collected from published literatures or statistical bureaus. A sensitivity analysis was conducted to explore the influence of parameters on the uncertainty of the model. Results: Compared with the no eradication therapy group, H. pylori eradication therapy prolonged an average of 4.52 QALYs (32.64 QALYs vs 28.12 QALYs) and saved $3227.07 ($2472.83 vs $5699.90). The cost-effectiveness analysis demonstrated that no H. pylori eradication therapy cost more and produced less QALYs. It was dominated by H. pylori eradication therapy. The one-way sensitive analyses proved that the results were robust to the fluctuations of the input parameters. Conclusion: H. pylori eradication therapy not only reduced the risk of gastric cancer in first-degree relatives of patients with gastric cancer but also was an economical strategy with lower costs and greater efficacy.Keywords
This publication has 30 references indexed in Scilit:
- Gastric cancer and family historyThe Korean Journal of Internal Medicine, 2016
- Identification of Helicobacter pylori and the evolution of an efficacious childhood vaccine to protect against gastritis and peptic ulcer diseasePediatric Research, 2016
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Pathobiology of Helicobacter pylori–Induced Gastric CancerGastroenterology, 2016
- Kyoto global consensus report onHelicobacter pylorigastritisGut, 2015
- Review article: the epidemiology and prevention of gastric cancerAlimentary Pharmacology & Therapeutics, 2014
- Global burden of gastric cancer attributable toHelicobacterpyloriInternational Journal of Cancer, 2014
- Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and PreventionCancer Epidemiology, Biomarkers & Prevention, 2014
- Cost-effectiveness analysis of Helicobacter pylori screening in prevention of gastric cancer in ChineseInternational Journal of Technology Assessment in Health Care, 2008
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998